Clinical Focus
Business Focus
Spotlight
Subscribe
CE/CME
- CDC News
- Adult Immunization
- Hepatology
- Rare Disorders
- Pediatric Immunization
- Weight Management
- Screening
- Psychiatry
- Allergy
- Women's Health
- Cardiology
- Pediatrics
- Kidney Disease
- Dermatology
- Endocrinology
- Pain Management
- Gastroenterology
- Geriatrics
- Infectious Disease
- Orthopedics
- Obesity Medicine
- Rheumatology
- Technology
- Oncology
- Nephrology
- Neurology
- Pulmonology
ASCVD Risk Hit Hard by COVID-19: A Lipidologist's View
Preventive cardiology and lipid specialist Seth J. Baum, MD, answers questions about the state of preventive cardiology in the midst of COVID-19.
Seth J. Baum, MD, discusses the "state of ASCVD risk assessment" in 2020 and highlights the potential COVID-19-related setbacks in cardiovascular health as healthy activity is limited, cooking and eating are ever-present in the media, and many individuals with chronic conditions, including hypertension, congestive heart failure, ACS, remain reluctant to make in-person appointments for follow-up.
______________________________________________________
Dr Baum is clinical professor, biomedical science, at the Florida Atlantic University Charles E. Schmidt College of Medicine; he is founder and chief medical officer of Excel Medical Clinical Trials, LLC, and past president of the American Society for Preventive Cardiology. He is in private practice i Boca Raton, FL, where he specializes in lipid disorders and cardiovascular disease prevention.
Related Videos
